CA2673435A1 - Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline - Google Patents
Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline Download PDFInfo
- Publication number
- CA2673435A1 CA2673435A1 CA002673435A CA2673435A CA2673435A1 CA 2673435 A1 CA2673435 A1 CA 2673435A1 CA 002673435 A CA002673435 A CA 002673435A CA 2673435 A CA2673435 A CA 2673435A CA 2673435 A1 CA2673435 A1 CA 2673435A1
- Authority
- CA
- Canada
- Prior art keywords
- disorder
- salt
- dementia
- delusional
- succinate salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The present invention relates to a succinate salt of 2-((4-(1-methyl-4- (pyridin-4-yl)-1 H-pyrazol-3-yl)phenoxy)methyl)quinoline, and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal the succinate salt. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and the succinate salt.
Claims (14)
1. A succinate salt of Formula I:
2. The salt according to claim 1, wherein the salt has characteristic X-ray powder diffraction peaks as measured with copper radiation of 2-Theta ~
0.1 °
of 15.8, 21.0 and 26.6.
0.1 °
of 15.8, 21.0 and 26.6.
3. The salt according to claim 1, wherein the salt has characteristic X-ray powder diffraction peaks as measured with copper radiation of 2-Theta ~
0.1 °
of 15.8, 16.7, 21.0, 24.2 and 26.6.
0.1 °
of 15.8, 16.7, 21.0, 24.2 and 26.6.
4. The salt according to claim 1, wherein the salt has the characteristic X-ray powder diffraction pattern of FIG. 1.
5. The salt according to claim 1, 2, 3 or 4, wherein the salt has a melting onset temperature of 184 ~ 3°C.
6. The salt according to claim 1, 2, 3, 4 or 5, wherein the salt increases in weight by less than 0.5% at 90 ~ 2% relative humidity in an isothermal (25.1 ~ 0.1 °C) moisture sorption test conducted from approximately 1%
to 90%
(~2%) humidity.
to 90%
(~2%) humidity.
7. The salt according to claim 1, 2, 3, 4, 5 or 6, wherein the salt is anhydrous.
8. A pharmaceutical composition comprising a succinate salt as defined in claim 1, 2, 3, 4, 5, 6 or 7, and a pharmaceutically acceptable carrier.
9. The pharmaceutical composition according to claim 8 wherein the succinate salt is crystalline.
10. A pharmaceutical composition for use in the treatment of a psychotic disorder, delusional disorder or drug induced psychosis; anxiety disorder, movement disorder, mood disorder, neurodegenerative disorder or drug addiction, comprising an amount of a succinate salt as defined in claim 1, 2, 3, 4, 5, 6 or 7 effective in treating said disorder or condition, and a pharmaceutically acceptable carrier.
11. Use of an effective amount of a succinate salt as defined in claim 1, 2, 3, 4, 5, 6 or 7 for the treatment of a psychotic disorder, delusional disorder or drug induced psychosis; anxiety disorder, movement disorder, mood disorder, or neurodegenerative disorder.
12. Use of an effective amount of a succinate salt as defined in claim 1, 2, 3, 4, 5, 6 or 7 for the treatment of dementia, Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drug-related dementia, dementia associated with intracranial tumors or cerebral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia; delirium; amnestic disorder; post-traumatic stress disorder; mental retardation; a learning disorder, reading disorder, mathematics disorder, or a disorder of written expression;
attention-deficit/hyperactivity disorder; age-related cognitive decline, major depressive episode of the mild, moderate or severe type; a manic or mixed mood episode; a hypomanic mood episode; a depressive episode with atypical features;
a depressive episode with melancholic features; a depressive episode with catatonic features; a mood episode with postpartum onset; post-stroke depression; major depressive disorder; dysthymic disorder; minor depressive disorder; premenstrual dysphoric disorder; post-psychotic depressive disorder of schizophrenia; a major depressive disorder superimposed on a psychotic disorder comprising a delusional disorder or schizophrenia; a bipolar disorder comprising bipolar I disorder, bipolar II disorder, cyclothymic disorder, Parkinson's disease;
Huntington's disease; dementia, Alzheimer's disease, multi-infarct dementia, AIDS-related dementia, Fronto temperal Dementia; neurodegeneration associated with cerebral trauma; neurodegeneration associated with stroke;
neurodegeneration associated with cerebral infarct; hypoglycemia-induced neurodegeneration; neurodegeneration associated with epileptic seizure;
neurodegeneration associated with neurotoxin poisoning; multi-system atrophy, paranoid, disorganized, catatonic, undifferentiated or residual type;
schizophreniform disorder; schizoaffective disorder of the delusional type or the depressive type; delusional disorder; substance-induced psychotic disorder, psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; or personality disorder of the schizoid type.
attention-deficit/hyperactivity disorder; age-related cognitive decline, major depressive episode of the mild, moderate or severe type; a manic or mixed mood episode; a hypomanic mood episode; a depressive episode with atypical features;
a depressive episode with melancholic features; a depressive episode with catatonic features; a mood episode with postpartum onset; post-stroke depression; major depressive disorder; dysthymic disorder; minor depressive disorder; premenstrual dysphoric disorder; post-psychotic depressive disorder of schizophrenia; a major depressive disorder superimposed on a psychotic disorder comprising a delusional disorder or schizophrenia; a bipolar disorder comprising bipolar I disorder, bipolar II disorder, cyclothymic disorder, Parkinson's disease;
Huntington's disease; dementia, Alzheimer's disease, multi-infarct dementia, AIDS-related dementia, Fronto temperal Dementia; neurodegeneration associated with cerebral trauma; neurodegeneration associated with stroke;
neurodegeneration associated with cerebral infarct; hypoglycemia-induced neurodegeneration; neurodegeneration associated with epileptic seizure;
neurodegeneration associated with neurotoxin poisoning; multi-system atrophy, paranoid, disorganized, catatonic, undifferentiated or residual type;
schizophreniform disorder; schizoaffective disorder of the delusional type or the depressive type; delusional disorder; substance-induced psychotic disorder, psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; or personality disorder of the schizoid type.
13. Use of an amount of the succinate salt as defined in claim 1, 2, 3, 4, 5, 6 or 7 effective in inhibiting PDE10 for the treatment of a psychotic disorder, delusional disorder or drug induced psychosis; anxiety disorder, movement disorder, mood disorder, neurodegenerative disorder or drug addiction.
14. Use of a succinate salt as defined in claim 1, 2, 3, 4, 5, 6 or 7 in the manufacture of a medicament for the treatment of a psychotic disorder, delusional disorder or drug induced psychosis; anxiety disorder, movement disorder, mood disorder, neurodegenerative disorder or drug addiction.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87126006P | 2006-12-21 | 2006-12-21 | |
| US60/871,260 | 2006-12-21 | ||
| PCT/IB2007/003819 WO2008084299A1 (en) | 2006-12-21 | 2007-12-03 | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2673435A1 true CA2673435A1 (en) | 2008-07-17 |
| CA2673435C CA2673435C (en) | 2012-10-09 |
Family
ID=39321475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2673435A Expired - Fee Related CA2673435C (en) | 2006-12-21 | 2007-12-03 | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8283471B2 (en) |
| EP (1) | EP2125786B1 (en) |
| JP (1) | JP5254602B2 (en) |
| KR (2) | KR20090092338A (en) |
| CN (1) | CN101611029B (en) |
| AR (1) | AR064417A1 (en) |
| AT (1) | ATE502028T1 (en) |
| AU (1) | AU2007343135B2 (en) |
| BR (1) | BRPI0720936A2 (en) |
| CA (1) | CA2673435C (en) |
| CY (1) | CY1111919T1 (en) |
| DE (1) | DE602007013294D1 (en) |
| DK (1) | DK2125786T3 (en) |
| ES (1) | ES2360014T3 (en) |
| HK (1) | HK1134670A1 (en) |
| IL (1) | IL199389A (en) |
| MX (1) | MX2009006528A (en) |
| NZ (1) | NZ577716A (en) |
| PL (1) | PL2125786T3 (en) |
| PT (1) | PT2125786E (en) |
| RU (1) | RU2430918C2 (en) |
| SI (1) | SI2125786T1 (en) |
| TW (1) | TWI359660B (en) |
| WO (1) | WO2008084299A1 (en) |
| ZA (1) | ZA200904230B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
| TWI396689B (en) * | 2008-11-14 | 2013-05-21 | Amgen Inc | Pyrazine derivatives as phosphodiesterase 10 inhibitors |
| US20120214842A1 (en) | 2011-02-18 | 2012-08-23 | Exonhit Therapeutics Sa | Methods for treating diseases of the retina |
| WO2014142322A1 (en) | 2013-03-15 | 2014-09-18 | 第一三共株式会社 | Benzothiophene derivative |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| KR102233916B1 (en) * | 2019-05-28 | 2021-03-30 | 주식회사 엘지생활건강 | Composition for Skin Moisturizing, Improving Skin Wrinkle and Elasticity comprising PQ1 Succinic Acid |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| DE60221642T3 (en) * | 2001-02-12 | 2017-10-26 | Wyeth LLC (n.d.Ges.d. Staates Delaware) | O-DESMETHYL-VENLAFAXINE SUCCINATE SALT |
| WO2003045394A1 (en) * | 2001-11-29 | 2003-06-05 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| NZ532436A (en) * | 2001-12-12 | 2006-01-27 | Pfizer Prod Inc | Salt forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
| US7767683B2 (en) * | 2003-08-18 | 2010-08-03 | H. Lundbeck A/S | Hydrogen succinate salts of trans-4-((1R, 3S)-6-chloro-3-phenylindan-1-YL)-1,2,2-trimethylpiperazine and the use as a medicament |
| JP4302762B2 (en) * | 2005-01-07 | 2009-07-29 | ファイザー・プロダクツ・インク | Heteroaromatic quinoline compounds and their use as PDE10 inhibitors |
| US20060165910A1 (en) | 2005-01-21 | 2006-07-27 | Cabot Corporation | Processes for forming nanoparticles |
| JP2009519952A (en) * | 2005-12-16 | 2009-05-21 | ワイス | Lyophilized composition of triazolopyrimidine compound |
-
2007
- 2007-12-03 KR KR1020097015193A patent/KR20090092338A/en not_active Application Discontinuation
- 2007-12-03 DK DK07858987.6T patent/DK2125786T3/en active
- 2007-12-03 PL PL07858987T patent/PL2125786T3/en unknown
- 2007-12-03 CA CA2673435A patent/CA2673435C/en not_active Expired - Fee Related
- 2007-12-03 MX MX2009006528A patent/MX2009006528A/en active IP Right Grant
- 2007-12-03 ES ES07858987T patent/ES2360014T3/en active Active
- 2007-12-03 US US12/515,612 patent/US8283471B2/en not_active Expired - Fee Related
- 2007-12-03 SI SI200730561T patent/SI2125786T1/en unknown
- 2007-12-03 KR KR1020127009903A patent/KR20120043775A/en not_active Application Discontinuation
- 2007-12-03 RU RU2009123347/04A patent/RU2430918C2/en not_active IP Right Cessation
- 2007-12-03 DE DE602007013294T patent/DE602007013294D1/en active Active
- 2007-12-03 NZ NZ577716A patent/NZ577716A/en not_active IP Right Cessation
- 2007-12-03 AT AT07858987T patent/ATE502028T1/en active
- 2007-12-03 BR BRPI0720936-3A patent/BRPI0720936A2/en not_active IP Right Cessation
- 2007-12-03 AU AU2007343135A patent/AU2007343135B2/en not_active Ceased
- 2007-12-03 CN CN200780051566.5A patent/CN101611029B/en not_active Expired - Fee Related
- 2007-12-03 EP EP07858987A patent/EP2125786B1/en not_active Not-in-force
- 2007-12-03 WO PCT/IB2007/003819 patent/WO2008084299A1/en active Application Filing
- 2007-12-03 PT PT07858987T patent/PT2125786E/en unknown
- 2007-12-18 AR ARP070105692A patent/AR064417A1/en not_active Application Discontinuation
- 2007-12-19 JP JP2007327323A patent/JP5254602B2/en not_active Expired - Fee Related
- 2007-12-20 TW TW096148920A patent/TWI359660B/en not_active IP Right Cessation
-
2009
- 2009-06-16 IL IL199389A patent/IL199389A/en active IP Right Review Request
- 2009-06-17 ZA ZA200904230A patent/ZA200904230B/en unknown
-
2010
- 2010-02-10 HK HK10101480.3A patent/HK1134670A1/en not_active IP Right Cessation
-
2011
- 2011-05-17 CY CY20111100481T patent/CY1111919T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009123347A (en) | 2011-01-27 |
| US8283471B2 (en) | 2012-10-09 |
| DK2125786T3 (en) | 2011-05-09 |
| KR20120043775A (en) | 2012-05-04 |
| PT2125786E (en) | 2011-04-21 |
| AU2007343135A1 (en) | 2008-07-17 |
| ATE502028T1 (en) | 2011-04-15 |
| SI2125786T1 (en) | 2011-05-31 |
| ZA200904230B (en) | 2010-04-28 |
| WO2008084299A1 (en) | 2008-07-17 |
| EP2125786B1 (en) | 2011-03-16 |
| TW200833337A (en) | 2008-08-16 |
| TWI359660B (en) | 2012-03-11 |
| DE602007013294D1 (en) | 2011-04-28 |
| JP5254602B2 (en) | 2013-08-07 |
| US20100063089A1 (en) | 2010-03-11 |
| PL2125786T3 (en) | 2011-07-29 |
| AU2007343135B2 (en) | 2013-03-21 |
| ES2360014T3 (en) | 2011-05-31 |
| KR20090092338A (en) | 2009-08-31 |
| CA2673435C (en) | 2012-10-09 |
| CN101611029B (en) | 2014-09-10 |
| IL199389A (en) | 2014-01-30 |
| AR064417A1 (en) | 2009-04-01 |
| EP2125786A1 (en) | 2009-12-02 |
| CN101611029A (en) | 2009-12-23 |
| HK1134670A1 (en) | 2010-05-07 |
| CY1111919T1 (en) | 2015-11-04 |
| RU2430918C2 (en) | 2011-10-10 |
| JP2008208114A (en) | 2008-09-11 |
| BRPI0720936A2 (en) | 2014-03-11 |
| NZ577716A (en) | 2012-10-26 |
| MX2009006528A (en) | 2009-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2673435A1 (en) | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline | |
| CA2592986A1 (en) | Heteroaromatic quinoline compounds | |
| AU2012328476B2 (en) | Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1 | |
| NZ603230A (en) | Nitrogen containing heteroaryl compounds | |
| CN103159738B (en) | The heteroaryl aroma compounds of alkynyl bridging and application thereof | |
| AU2007223801A1 (en) | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors | |
| NZ592508A (en) | Pyrazine compounds as phosphodiesterase 10 inhibitors | |
| WO2009158467A3 (en) | Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors | |
| JP2012510437A5 (en) | ||
| PH12017501588A1 (en) | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof | |
| WO2009135651A8 (en) | 6-pyridin-3-yl-3,4-dihydro-1h-quinolin-2-one derivatives and related compounds as inhibitors of the human aldosterone synthase cyp11b2 | |
| EA200800975A1 (en) | Pyrimidinylamide Compounds (Variants) Including Their Pharmaceutical Composition and Method for the Treatment of Disorder Mediated by α4-Integrin | |
| JP2008208114A5 (en) | ||
| HRP20170570T1 (en) | Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists | |
| CA2876979A1 (en) | Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors | |
| CN104884448A (en) | Heteroaryl linked quinolinyl modulators of roryt | |
| WO2014145887A8 (en) | Benzimidazole derivatives and uses thereof | |
| AU2014368601B2 (en) | Quinazolin-THF-amines as PDE1 inhibitors | |
| WO2017100593A1 (en) | Thienopyrimidinone nmda receptor modulators and uses thereof | |
| WO2006087634A3 (en) | Uses of human autism susceptibility gene encoding a kinase | |
| NZ593058A (en) | (r)-3-(e)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy) pyridine, its salts, its synthesis and its use as ligand for nicotinic acetylcholinergic receptors | |
| AU2008313776B2 (en) | Trisubstituted 1,2,4-triazoles | |
| EP1958939A3 (en) | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | |
| IL205045A0 (en) | Piperidinyl and piperazinyl modulators of ?? - secretase | |
| WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20191203 |